Agilent Technologies Completes Large-Scale Expansion of Nucleic Acid Manufacturing Capacity
News May 08, 2009
Agilent Technologies Inc. has announced that a major expansion of its Nucleic Acids Solutions Division (NASD) is complete, enabling the company to manufacture several hundred kilograms of therapeutic oligonucleotides per year. This production capacity allows Agilent to meet customers’ supply needs from preclinical and clinical studies through commercial launch, the company says.
NASD now offers a full range of manufacturing capacities for flexible production from grams to hundreds of kilograms of oligonucleotide active pharmaceutical ingredients (APIs). This is the second manufacturing expansion of the Boulder, Colo., facility since Agilent purchased the business in 2006, and involves the addition of large scale nucleic acid synthesis, purification and drying capacity.
“We now have the ability to meet our customers’ growing needs with facilities, equipment and expertise across a broad range of nucleic acid APIs,” said James Powell, NASD general manager.
Agilent’s capacity expansion features the addition of a 1 mol synthesizer capable of producing kilo quantities of API per synthesis batch. Equivalent downstream processing including chromatography, ultrafiltration and lyophilization has also been installed. Corresponding infrastructure and reaction vessels were added for custom conjugation chemistries and duplex annealing of siRNAs.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.